Defining SaeR/S-dependent Neutrophil-S. aureus Interactions that Determine the Outcome of Infection
定义 SaeR/S 依赖性中性粒细胞-S。
基本信息
- 批准号:10408775
- 负责人:
- 金额:$ 60.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-16 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAntibiotic ResistanceAntibioticsApoptosisAutophagocytosisBacterial GenesBacterial InfectionsCell CommunicationCell Culture SystemCell Culture TechniquesCellsCommunitiesComplementCytolysisDataDevelopmentDiseaseDrug resistanceEffectivenessEnvironmentEventFoundationsFunctional disorderFutureGene ExpressionGenesGenetic TranscriptionHigh PrevalenceHospitalsHumanImmuneImmune responseImmunotherapeutic agentIndividualInfectionInflammation MediatorsIntelligenceLifeLinkMediatingMethodsModelingMolecularMorbidity - disease rateNatural ImmunityNecrotizing fasciitisNeutrophil InfiltrationOutcomeOutpatientsPathogenesisPathway interactionsPeripheral Blood Mononuclear CellPeroxidasesPhagocytosisPlayPopulationProductionPublic HealthPublishingRNAReactive Oxygen SpeciesRegulationRegulator GenesReportingResearchResistance developmentRiskRoleSepsisSeveritiesSignal TransductionSkinSoft Tissue InfectionsStaphylococcus aureusStaphylococcus aureus infectionSystemTNF geneTestingTherapeuticTimeTranscriptUp-RegulationVaccinesVirulenceVisitantimicrobialbaseclinically significantcombatcommunity settingdesignemerging pathogenexperimental studyextracellularimprovedin vivoleukotoxinmonocytemortalitymouse modelneutrophilnext generation sequencingnovelnovel therapeuticsnovel vaccinespathogenpreventresponsesensory systemskin abscesstranscriptometranscriptome sequencing
项目摘要
Staphylococcus aureus (S. aureus) is one of the most frequent causes of bacterial infections in the U.S. and is
responsible for diverse types of infections ranging in severity from mild to fatal in both hospital and community
settings. In the community, S. aureus typically causes skin-and-soft-tissue infections with an estimated 12 –
13 million outpatient visits per-year (in the U.S.) but can also cause severe manifestations including necrotizing
fasciitis and sepsis in individuals with no underlying risk. One of the most clinically significant aspects of S.
aureus infections is the high prevalence of drug resistance and the innate ability for S. aureus to develop
resistance to antibiotics making it very difficult to develop therapeutics that will have potential for long-term
efficacy on S. aureus. The research proposed in this application will broaden our understanding of host-
pathogen interactions, providing the foundation for future studies aimed at the intelligent design of novel
vaccines and therapies to treat bacterial infection. To that end, this project will study how S. aureus uses the
SaeR/S two-component gene regulatory system to evade innate immunity. The SaeR/S system is essential for
evasion of neutrophil killing; however, exact mechanisms dependent on SaeR/S resulting in neutrophil
dysfunction are not defined. Three specific Aims will test the hypothesis that the SaeR/S-mediated up-
regulation of S. aureus virulence genes undermines an effective neutrophil response that would normally clear
infection. In Aim One, host pathogen RNA expression via RNA-seq will be used to determine the direct
influence of SaeR/S-regulated bacterial genes on human neutrophil gene expression as well as resolve the
individual contribution of SaeR/S components on neutrophil and pathogen gene expression simultaneously. In
Aim Two, we will determine how SaeR/S-dependent changes in neutrophil human myeloperoxidase (MPO)
activity and the production reactive oxygen species (ROS) alters neutrophil apoptosis and neutrophil
extracellular trap (NET) formation. In Aim Three, we will utilize a novel ex vivo model of neutrophil priming by
stimulated PBMCs to determine the role of initial SaeR/S-mediated immune cell interactions on subsequent
neutrophil function. These ex vivo primary human cell studies will be complemented with murine models of
infection to thoroughly evaluate these immune responses. Findings from experiments outlined in this proposal
will improve our overall understanding of host-pathogen interactions by specifically characterizing novel
SaeR/S-mediated mechanisms used by S. aureus to overcome an effective neutrophil response. Collectively
this research will address our long-term objective to characterize reciprocal response pathways between host
and pathogen that will highlight key factors needed for both the pathogen to cause infection and for the host to
resolve disease. Results will provide valuable information for vaccine and immunotherapeutic development.
金黄色葡萄球菌 (S. aureus) 是美国细菌感染最常见的原因之一,
在医院和社区造成多种类型的感染,严重程度从轻微到致命
在社区中,金黄色葡萄球菌通常会导致皮肤和软组织感染,估计有 12 –
每年门诊量达 1300 万人次(在美国),但也可能导致严重的症状,包括坏死
无潜在风险的个体中的筋膜炎和败血症是链球菌最具有临床意义的方面之一。
金黄色葡萄球菌感染是耐药性的高发生率和金黄色葡萄球菌天生的发展能力
对抗生素的耐药性使得开发具有长期潜力的治疗方法变得非常困难
本申请中提出的研究将拓宽我们对宿主的理解。
病原体相互作用,为未来旨在智能设计新型病原体的研究奠定了基础
为此,该项目将研究金黄色葡萄球菌如何使用细菌感染的疫苗和疗法。
SaeR/S双组分基因调控系统对于逃避先天免疫至关重要。
逃避中性粒细胞杀伤;然而,确切的机制依赖于 SaeR/S 导致中性粒细胞
功能障碍尚未定义。三个具体目标将检验 SaeR/S 介导的上行假设。
金黄色葡萄球菌毒力基因的调节破坏了通常会清除的有效中性粒细胞反应
在目标一中,通过 RNA-seq 的宿主病原体 RNA 表达将用于确定直接感染。
SaeR/S 调节的细菌基因对人中性粒细胞基因表达的影响,并解决了
SaeR/S 成分同时对中性粒细胞和病原体基因表达的个体贡献。
目标二,我们将确定中性粒细胞人髓过氧化物酶 (MPO) 中 SaeR/S 依赖性变化如何
活性氧 (ROS) 的活性和产生改变中性粒细胞凋亡和中性粒细胞
在目标三中,我们将利用一种新型的中性粒细胞启动体外模型。
刺激 PBMC 以确定初始 SaeR/S 介导的免疫细胞相互作用对后续的作用
这些离体原代人类细胞研究将得到小鼠模型的补充。
感染以彻底评估本提案中概述的实验结果。
将通过具体表征新的宿主-病原体相互作用来提高我们对宿主-病原体相互作用的整体理解
金黄色葡萄球菌使用 SaeR/S 介导的机制来克服有效的中性粒细胞集体反应。
这项研究将解决我们的长期目标,即描述宿主之间的相互反应途径
和病原体,将突出病原体引起感染和宿主感染所需的关键因素
解决疾病。结果将为疫苗和免疫治疗的开发提供有价值的信息。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tyler K Nygaard其他文献
Tyler K Nygaard的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tyler K Nygaard', 18)}}的其他基金
Defining SaeR/S-dependent Neutrophil-S. aureus Interactions that Determine the Outcome of Infection
定义 SaeR/S 依赖性中性粒细胞-S。
- 批准号:
10624864 - 财政年份:2020
- 资助金额:
$ 60.9万 - 项目类别:
Defining SaeR/S-dependent Neutrophil-S. aureus Interactions that Determine the Outcome of Infection
定义 SaeR/S 依赖性中性粒细胞-S。
- 批准号:
10194360 - 财政年份:2020
- 资助金额:
$ 60.9万 - 项目类别:
Defining SaeR/S-dependent Neutrophil-S. aureus Interactions that Determine the Outcome of Infection
定义 SaeR/S 依赖性中性粒细胞-S。
- 批准号:
10058515 - 财政年份:2020
- 资助金额:
$ 60.9万 - 项目类别:
相似国自然基金
靶向铜绿假单胞菌FpvA蛋白的铁载体偶联抗生素克服细菌耐药性及作用机制研究
- 批准号:82304313
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
多环芳烃影响大肠杆菌抗生素耐药性进化的分子机制
- 批准号:32301424
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
乙醇脱氢酶AdhB介导肺炎链球菌抗生素耐药性的机制研究
- 批准号:32300154
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
鸭肠道菌群抗生素耐药性分布及替抗噬菌体内溶素鉴定研究
- 批准号:32360830
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
胞外DNA对厌氧颗粒污泥抗生素耐药性转移的影响及作用机制
- 批准号:
- 批准年份:2022
- 资助金额:54 万元
- 项目类别:面上项目
相似海外基金
Molecular basis of glycan recognition by T and B cells
T 和 B 细胞识别聚糖的分子基础
- 批准号:
10549648 - 财政年份:2023
- 资助金额:
$ 60.9万 - 项目类别:
A Randomized Pilot and Feasibility Study of a cultuRE-Directed approach to Urinary traCT Infection symptoms in older womeN: a mixed methods evaluation - the REDUCTION trial
针对老年女性尿路感染症状的文化导向方法的随机试验和可行性研究:混合方法评估 - REDUCTION 试验
- 批准号:
10586250 - 财政年份:2023
- 资助金额:
$ 60.9万 - 项目类别:
Structural and functional characterization of glycosyltransferases in the Campylobacter concisus N-linked glycoconjugate biosynthetic pathway
弯曲杆菌 N 连接糖复合物生物合成途径中糖基转移酶的结构和功能表征
- 批准号:
10607139 - 财政年份:2023
- 资助金额:
$ 60.9万 - 项目类别:
An RNA Nanosensor for the Diagnosis of Antibiotic Resistance in M. Tuberculosis
用于诊断结核分枝杆菌抗生素耐药性的 RNA 纳米传感器
- 批准号:
10670613 - 财政年份:2023
- 资助金额:
$ 60.9万 - 项目类别:
Development of Targeted Antipseudomonal Bactericidal Prodrugs
靶向抗假单胞菌杀菌前药的开发
- 批准号:
10678074 - 财政年份:2023
- 资助金额:
$ 60.9万 - 项目类别: